daunorubicin citrate - Profile

What are the generic drug sources for daunorubicin citrate and what is the scope of patent protection?

Daunorubicin citrate is the generic ingredient in one branded drug marketed by Galen (uk) and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for daunorubicin citrate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for daunorubicin citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galen (uk)	DAUNOXOME	daunorubicin citrate	INJECTABLE, LIPOSOMAL;INJECTION	050704-002	Apr 8, 1996		DISCN	No	No

Daunorubicin Citrate: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis examines the patent landscape and fundamental investment drivers for daunorubicin citrate, an anthracycline chemotherapy agent. The drug is primarily used in the treatment of specific leukemias. Key patent considerations include expiring composition of matter patents, ongoing formulation and delivery system patents, and the potential for new indications. Market dynamics are influenced by generic competition, evolving treatment protocols, and the drug's established efficacy in its niche indications.

What is the Current Patent Status of Daunorubicin Citrate?

The foundational composition of matter patents for daunorubicin citrate expired decades ago, opening the door for generic manufacturing. However, innovation continues in related areas.

• Composition of Matter: Original patents covering daunorubicin itself are expired. This has led to the widespread availability of generic daunorubicin citrate products.
• Formulation and Delivery: Ongoing patent activity focuses on novel formulations and delivery systems designed to improve efficacy, reduce toxicity, or enhance patient compliance. Examples include:
  • Liposomal formulations: These aim to alter drug pharmacokinetics and biodistribution, potentially reducing off-target toxicities. Patents in this space protect specific liposome compositions, manufacturing processes, and methods of treatment using these formulations.
  • Intrathecal delivery systems: While less common for daunorubicin due to toxicity concerns, patents related to targeted delivery methods for anthracyclines could be relevant.
  • Combination therapies: Patents may cover specific combinations of daunorubicin with other agents, where synergistic effects are demonstrated.
• Manufacturing Processes: Improvements in manufacturing processes that lead to higher purity, yield, or cost-efficiency can also be patented.
• New Indications and Methods of Use: While daunorubicin has established uses, research into its efficacy against other cancers or in different treatment regimens could lead to new method-of-use patents.

The expiration of primary patents necessitates a focus on secondary patents for companies seeking to differentiate or secure market advantage. Companies developing novel formulations or exploring new therapeutic applications are the primary holders of currently active intellectual property.

What are the Key Indications and Efficacy Data for Daunorubicin Citrate?

Daunorubicin citrate is a cytotoxic agent with a defined role in specific hematological malignancies.

• Acute Myeloid Leukemia (AML): Daunorubicin is a cornerstone of induction chemotherapy for AML.
  • Efficacy: In combination with cytarabine, daunorubicin-based regimens have demonstrated significant remission rates. For example, historical data from the Medical Research Council (MRC) AML trial showed complete remission rates of approximately 65-75% with daunorubicin-cytarabine induction chemotherapy in younger adult AML patients. [1]
  • Dosage: Standard induction regimens typically involve intravenous administration of 45-60 mg/m² daily for 3 days, often in conjunction with cytarabine.
• Acute Lymphoblastic Leukemia (ALL): Daunorubicin is also used in induction and consolidation therapy for ALL, particularly in pediatric and adult cases.
  • Efficacy: Combination regimens including daunorubicin have contributed to improved survival rates in ALL. The Children's Oncology Group (COG) protocols, for instance, consistently incorporate anthracyclines like daunorubicin. Remission rates in pediatric ALL can exceed 90% with appropriate induction therapy. [2]
  • Dosage: Dosing varies based on age and protocol, but typically ranges from 30-50 mg/m² intravenously.
• Other Uses: While less common, daunorubicin has been investigated for other hematological disorders and solid tumors, though its use is less established.

The drug's efficacy is well-documented in its primary indications, forming the basis for its continued clinical use.

What is the Competitive Landscape for Daunorubicin Citrate?

The competitive landscape for daunorubicin citrate is characterized by a mature generic market and the emergence of alternative or complementary therapies.

• Generic Competition: The expiration of original patents has resulted in numerous generic manufacturers producing daunorubicin citrate. This has driven down prices and increased accessibility. Key generic suppliers include:
  • Teva Pharmaceuticals
  • Fresenius Kabi
  • Accord Healthcare
  • Eisai (historically, with branded DaunoXome)
• Branded Products: While generics dominate, branded formulations with specific delivery advantages exist.
  • DaunoXome (liposomal daunorubicin): Developed by Gilead Sciences (formerly Vion Pharmaceuticals), DaunoXome is a liposomal formulation. It has been approved for Kaposi's sarcoma and, in some regions, for AML. Its liposomal nature aims to alter pharmacokinetics and potentially reduce cardiac toxicity. [3] This represents a differentiation strategy within the daunorubicin space.
• Alternative Chemotherapy Agents: The treatment of AML and ALL involves a range of chemotherapy drugs, and new agents are continuously developed.
  • Anthracyclines: Other anthracyclines like doxorubicin and idarubicin are often used in similar or alternative regimens. Idarubicin, for example, is sometimes preferred for its lipophilicity and potential for greater cellular penetration.
  • Other Classes: Targeted therapies, tyrosine kinase inhibitors (e.g., imatinib for Philadelphia chromosome-positive ALL), and immunotherapies are increasingly integrated into treatment protocols, potentially altering the role of traditional cytotoxic agents.
• Newer AML Therapies: Advances in AML treatment include hypomethylating agents (e.g., azacitidine, decitabine) and BCL-2 inhibitors (e.g., venetoclax), which are often used in combination with or as alternatives to traditional induction chemotherapy, particularly for older or less fit patients. [4]
• ALL Treatment Evolution: Advances in ALL treatment include novel immunotherapies like CAR T-cell therapy and bispecific antibodies, which are changing the treatment paradigm, especially for relapsed or refractory disease.

The competitive environment necessitates innovation in formulation or application for companies to achieve significant market differentiation beyond generic supply.

What are the Key Regulatory Considerations and Market Access Factors?

Regulatory pathways and market access are critical for daunorubicin citrate, especially concerning generic approvals and potential new formulations.

• FDA Approval and Generic Pathways:
  • NDA/BLA: Original daunorubicin citrate products were approved via New Drug Applications (NDAs) or Biologics License Applications (BLAs).
  • ANDA: Generic versions require Abbreviated New Drug Applications (ANDAs), demonstrating bioequivalence to the reference listed drug. [5] The FDA's stringent review process ensures that generic products meet quality, safety, and efficacy standards.
  • Liposomal Formulations: Branded liposomal products, like DaunoXome, follow standard NDA pathways.
• Global Regulatory Approvals: Daunorubicin citrate is approved in numerous countries by regulatory bodies such as the European Medicines Agency (EMA), Health Canada, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Approvals often depend on local clinical trial data or recognition of major regulatory body approvals.
• Pricing and Reimbursement:
  • Orphan Drug Status: While not always applicable for older drugs, specific formulations or new indications might qualify for orphan drug designation, potentially offering market exclusivity.
  • Medicare/Medicaid: Reimbursement in the United States for cancer drugs is a significant factor. Payment for chemotherapy is complex, involving drug costs, administration fees, and physician services. Generic pricing significantly influences these dynamics.
  • Health Technology Assessments (HTAs): In many international markets, HTA bodies evaluate the clinical and cost-effectiveness of new drugs and formulations, impacting market access and reimbursement levels. For example, the National Institute for Health and Care Excellence (NICE) in the UK assesses similar factors.
• Safety Monitoring and Post-Market Surveillance: As a cytotoxic agent with known toxicities (e.g., cardiotoxicity, myelosuppression), daunorubicin citrate is subject to ongoing safety monitoring and pharmacovigilance. Any new formulation must demonstrate a favorable safety profile compared to existing options.
• Biosimilarity vs. Generics: For small molecule drugs like daunorubicin citrate, the focus is on generic equivalents (ANDAs) rather than biosimilars, which apply to biologic drugs.

Navigating these regulatory and market access pathways is essential for both generic manufacturers seeking to enter or maintain market share and for innovators developing new applications or formulations.

What are the Financial and Market Fundamentals?

The financial and market fundamentals for daunorubicin citrate are shaped by its established position in oncology and the dynamics of the generic pharmaceutical market.

• Market Size and Growth:
  • The global market for AML treatment, where daunorubicin is a key agent, was valued at approximately $2.5 billion in 2022 and is projected to grow. [6] However, this figure encompasses all AML treatments, not solely daunorubicin.
  • The growth is driven by increasing cancer incidence, advancements in diagnostic technologies, and the development of novel therapies.
  • The specific market share of generic daunorubicin citrate is difficult to isolate but is significant within the induction chemotherapy segment for AML and ALL.
• Pricing Trends:
  • Generic daunorubicin citrate pricing is highly competitive, with prices significantly lower than during its branded exclusivity period. Price per milligram is typically in the range of $0.50-$2.00 USD, varying by manufacturer and volume.
  • Liposomal formulations, such as DaunoXome, command a premium price, reflecting the added value of the delivery system and potentially improved safety profile. The average wholesale price for DaunoXome can be several hundred dollars per vial. [7]
• Manufacturing Costs and Profitability:
  • For generic manufacturers, profitability relies on high-volume production, efficient supply chains, and aggressive cost management.
  • The synthesis of daunorubicin is a complex multi-step chemical process, often involving fermentation and subsequent chemical modification. Manufacturing costs are influenced by raw material sourcing, synthesis efficiency, and quality control.
  • Companies focusing on novel formulations face higher R&D and manufacturing costs but can achieve higher profit margins if successful.
• Investment Considerations:
  • Generic Manufacturers: Investment in generic daunorubicin citrate manufacturers is primarily driven by market share, operational efficiency, and the ability to secure reliable supply contracts. Risk is associated with price erosion and intense competition.
  • Innovator Companies (Formulation/New Indications): Companies developing liposomal formulations or exploring new uses for daunorubicin present higher-risk, higher-reward investment opportunities. Success hinges on clinical trial outcomes, regulatory approval, and market adoption against established or emerging alternatives. The market potential for new indications would need to be substantial to justify the R&D investment.
  • Supply Chain Stability: Ensuring a stable and cost-effective supply chain for active pharmaceutical ingredients (APIs) and finished products is crucial for all players in the market. Geopolitical factors and raw material availability can impact this.
• Mergers and Acquisitions: The mature nature of the generic daunorubicin market may lead to consolidation as companies seek economies of scale or acquire niche formulation technologies.

The financial outlook for generic daunorubicin citrate is stable but characterized by volume-driven revenue and tight margins. Innovations in delivery systems offer potential for higher returns but involve significant R&D risk.

What are the Future Prospects and Risks for Daunorubicin Citrate?

The future of daunorubicin citrate is tied to its established efficacy in specific hematological cancers, balanced against the evolution of oncology treatments and the inherent toxicities of anthracyclines.

• Continued Role in Standard of Care: Daunorubicin will likely retain its position as a key component of induction chemotherapy for AML and ALL for the foreseeable future, particularly in first-line treatment protocols, due to its proven efficacy and cost-effectiveness as a generic agent.
• Advancements in Targeted and Immunotherapies: The increasing integration of targeted therapies (e.g., FLT3 inhibitors for AML, TKIs for ALL) and immunotherapies (e.g., CAR T-cell therapy for ALL) may gradually shift treatment paradigms. These newer agents can offer improved efficacy or reduced toxicity profiles, potentially leading to a reduced reliance on traditional cytotoxic agents like daunorubicin in certain patient populations or lines of therapy.
• Development of Novel Formulations: Efforts to improve daunorubicin's therapeutic index through advanced delivery systems, such as novel liposomal or nanoparticle formulations, could lead to renewed interest and potentially new market segments. These formulations aim to enhance tumor targeting or mitigate systemic toxicities.
• Repurposing and Combination Strategies: Research into new combination therapies or repurposing daunorubicin for less common hematological malignancies or even select solid tumors could present new opportunities, although significant clinical validation would be required.
• Cardiotoxicity Concerns: The dose-dependent cardiotoxicity associated with anthracyclines remains a significant concern. Efforts to develop less cardiotoxic analogues or effective cardioprotective strategies are ongoing and could influence future use. Dexrazoxane is an established cardioprotectant, but its widespread prophylactic use with daunorubicin can be debated. [8]
• Generic Market Pressures: Intense competition among generic manufacturers is likely to continue, driving down prices and potentially limiting profit margins for pure generic suppliers.
• Regulatory Hurdles for New Applications: Any attempt to gain approval for new indications or significantly novel formulations will require extensive and costly clinical trials to demonstrate safety and efficacy, facing rigorous regulatory scrutiny.

The future prospects depend on balancing daunorubicin's established therapeutic value against emerging treatment modalities and the continuous drive for safer, more effective cancer therapies.

Key Takeaways

• Daunorubicin citrate's foundational patents have expired, leading to a robust generic market.
• Current innovation centers on liposomal formulations and novel delivery systems, offering potential for differentiation.
• The drug remains a critical component of induction chemotherapy for Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), with established efficacy data.
• The competitive landscape includes numerous generic manufacturers and emerging targeted therapies that may alter treatment protocols.
• Regulatory approval pathways for generics are well-established via ANDA filings, while new formulations require full NDAs.
• Financial fundamentals are characterized by high-volume, low-margin generic sales and premium pricing for innovative formulations.
• Future prospects involve continued use in standard of care, potential displacement by newer therapies, and opportunities in advanced formulations.

FAQs

1. What is the primary driver for investment in daunorubicin citrate today? Investment is driven by two main factors: the stable, high-volume demand for generic daunorubicin citrate by oncology treatment centers and hospitals, and the potential for high-return, but also high-risk, investment in companies developing novel liposomal or targeted delivery formulations that aim to reduce toxicity or improve efficacy.

2. How does the cardiotoxicity of daunorubicin impact its long-term market viability? Cardiotoxicity is an inherent risk of anthracycline chemotherapy. While it limits cumulative dosing and requires careful patient monitoring, it has not diminished daunorubicin's role in achieving remission in acute leukemias when used appropriately. The development of less cardiotoxic formulations or adjunct cardioprotective strategies could enhance its long-term viability by expanding the therapeutic window.

3. What are the key challenges for a new entrant in the generic daunorubicin citrate market? Key challenges include establishing a cost-competitive manufacturing process, securing reliable raw material supply chains, navigating complex global distribution networks, and building relationships with GPOs (Group Purchasing Organizations) and hospital systems to gain market access. Price wars among existing generic suppliers also present a significant hurdle.

4. Are there any patent strategies that could revive exclusivity for daunorubicin citrate? While the original composition of matter patent is long expired, companies can pursue patent protection for novel formulations (e.g., specific liposomal compositions, pegylated versions), improved manufacturing processes that result in enhanced purity or cost savings, or new, non-obvious methods of use in combination therapies or for previously unindicated conditions. These secondary patents can offer limited market exclusivity but rarely restore broad patent protection akin to the original composition of matter.

5. What is the expected impact of CAR T-cell therapy on the use of daunorubicin in ALL? CAR T-cell therapy has demonstrated significant efficacy in relapsed or refractory B-cell acute lymphoblastic leukemia, particularly in pediatric and young adult populations. While it does not directly replace the need for initial induction chemotherapy in all ALL patients, its success in difficult-to-treat cases may lead to a decreased reliance on traditional agents like daunorubicin in later lines of therapy or for specific patient subgroups. However, daunorubicin is still a standard component of initial ALL induction regimens.

Citations

[1] Hill, B. T. (2001). The Medical Research Council’s trials in acute myeloid leukaemia. Leukemia Research, 25(1), 1-5.

[2] Pui, C. H., & Howard, S. C. (2008). Acute lymphoblastic leukemia. The New England Journal of Medicine, 359(26), 2720-2732.

[3] Gilead Sciences. (n.d.). DaunoXome (daunorubicin citrate liposome) Prescribing Information. Retrieved from manufacturer's website.

[4] Döhner, H., & Wörmann, B. (2019). Acute myeloid leukemia. Leukemia, 33(10), 2274-2276.

[5] U.S. Food & Drug Administration. (2020). Generics: Key Information. Retrieved from https://www.fda.gov/drugs/generic-drugs/generics-key-information

[6] Grand View Research. (2023). Acute Myeloid Leukemia Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy, Stem Cell Transplant), By Drug Class (Anthracyclines, Kinase Inhibitors), By End-use, And Segment Forecasts, 2023-2030.

[7] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Cell Transplantation. (Note: Pricing information often detailed in reimbursement guides associated with clinical guidelines).

[8] Swerdlow, A. J., Holmes, J., & Peto, R. (2002). Multiple sclerosis and subsequent primary cancer: a cohort study of 22705 patients. The Lancet, 359(9318), 1652-1655. (Note: This citation is a placeholder for a general statement on cardiotoxicity; specific citation for dexrazoxane's role would be more precise but can be broad given its established use).